The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States.
Care-partners
Health-related quality of life
Humanistic burden
Immunoglobulin A nephropathy
Kidney disease
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
accepted:
11
10
2024
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
27
10
2024
Statut:
aheadofprint
Résumé
This cross-sectional survey study quantified the humanistic burden of immunoglobulin A nephropathy (IgAN), in terms of physical and mental health-related quality of life (HRQoL) and work productivity, among adults with primary IgAN and their care-partners. HRQoL was assessed (01/31/22 - 05/31/23) with validated tools including the KDQoL-36 (with SF-12), GAD-7 (anxiety), PHQ-9 (depression), and WPAI: SHP (work productivity). Participant characteristics and total/domain scores were summarized; selected outcomes were compared to an external, kidney disease-free cohort. 117 adults with IgAN and their care-partner pairs, and one adult without a care-partner, were included. The mean ages of patients and care-partners were 38.0 (SD: 8.6) and 40.2 (11.8) years, respectively; 55.9% and 43.6% were female. Mean physical and mental SF-12 scores for patients were 46.7 (SD: 8.0) and 41.9 (9.2), respectively, and 50.7 (7.3) and 43.7 (10.24) for care-partners. Both SF-12 components for patients, and the mental component for care-givers, were significantly worse compared to the US general population. Among patients, 27.1% had moderate/severe anxiety and 49.2% reported at least moderate depression. Compared to external controls, patients experienced significantly higher severity of anxiety (6.6 vs. 5.4) and depression (8.1 vs. 6.6; both p < 0.0001). Among care-partners, 13.7% experienced moderate anxiety and 37.8% experienced moderate/moderately-severe depression. Among employed individuals, both groups reported IgAN-related absenteeism (8.8-9.4%), presenteeism (25.1-25.9%), and overall work impairment (30.4-30.5%). US adults with IgAN and their care partners experience impairments to mental and physical HRQoL and heightened levels of depression and anxiety, underscoring the need for effective IgAN therapies and care-partner support.
Identifiants
pubmed: 39461930
doi: 10.1007/s11136-024-03813-x
pii: 10.1007/s11136-024-03813-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Travere Therapeutics, Inc.
ID : Travere Therapeutics, Inc.
Informations de copyright
© 2024. The Author(s).
Références
Wyatt, R. J., & Julian, B. A. (2013). IgA nephropathy. New England Journal of Medicine, 368(25), 2402–2414.
doi: 10.1056/NEJMra1206793
pubmed: 23782179
Kwon, C. S., Daniele, P., Forsythe, A., & Ngai, C. (2021). A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res, 8(2), 36–45.
doi: 10.36469/jheor.2021.26129
pubmed: 34692885
pmcid: 8410133
Nair, R., & Walker, P. D. (2006). Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney International, 69(8), 1455–1458.
doi: 10.1038/sj.ki.5000292
pubmed: 16531983
McGrogan, A., Franssen, C. F., & de Vries, C. S. (2011). The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrology, Dialysis, Transplantation, 26(2), 414–430.
doi: 10.1093/ndt/gfq665
pubmed: 21068142
Rodrigues, J. C., Haas, M., & Reich, H. N. (2017). IgA nephropathy. Clinical Journal of the American Society of Nephrology, 12(4), 677–686.
doi: 10.2215/CJN.07420716
pubmed: 28159829
pmcid: 5383386
Donadio, J. V., & Grande, J. P. (2002). IgA nephropathy. New England Journal of Medicine, 347(10), 738–748.
doi: 10.1056/NEJMra020109
pubmed: 12213946
Xie, J., Kiryluk, K., Wang, W., Wang, Z., Guo, S., Shen, P., et al. (2012). Predicting progression of IgA nephropathy: New clinical progression risk score. PLOS One, 7(6), e38904.
doi: 10.1371/journal.pone.0038904
pubmed: 22719981
pmcid: 3375310
Schwarzwälder, U., Hauk, M., & Zeller, T. (2009). RADAR - A randomised, multi-centre, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with haemodynamically relevant atherosclerotic renal artery stenosis. Trials, 10, 60.
doi: 10.1186/1745-6215-10-60
pubmed: 19635148
pmcid: 2724429
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., et al. (2023). Long-term outcomes in IgA nephropathy. Clinical Journal of the American Society of Nephrology, 18(6), 727–738.
doi: 10.2215/CJN.0000000000000135
pubmed: 37055195
pmcid: 10278810
Zelmer, J. L. (2007). The economic burden of end-stage renal disease in Canada. Kidney International, 72(9), 1122–1129.
doi: 10.1038/sj.ki.5002459
pubmed: 17700643
Ismail, H., Abdul Manaf, M. R., Abdul Gafor, A. H., Mohamad Zaher, Z. M., & Ibrahim, A. I. N. (2019). Economic burden of ESRD to the Malaysian health care system. Kidney Int Rep, 4(9), 1261–1270.
doi: 10.1016/j.ekir.2019.05.016
pubmed: 31517145
pmcid: 6732754
Strauss, W. E., & Auerbach, M. (2018). Health-related quality of life in patients with iron deficiency anemia: Impact of treatment with intravenous iron. Patient Relat Outcome Meas, 9, 285–298.
doi: 10.2147/PROM.S169653
pubmed: 30214332
pmcid: 6118263
van Haalen, H., Jackson, J., Spinowitz, B., Milligan, G., & Moon, R. (2020). Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: Analysis of multinational real-world data. Bmc Nephrology, 21(1), 88.
doi: 10.1186/s12882-020-01746-4
pubmed: 32143582
pmcid: 7060645
Hedayati, S. S., Minhajuddin, A. T., Toto, R. D., Morris, D. W., & Rush, A. J. (2009). Prevalence of major depressive episode in CKD. American Journal of Kidney Diseases, 54(3), 424–432.
doi: 10.1053/j.ajkd.2009.03.017
pubmed: 19493599
pmcid: 3210064
Zhao, Y., Chen, Y. P., Wu, Y. Q., Bao, B. Y., & Fan, H. (2020). Effect of physical activity on depression symptoms in patients with IgA nephropathy. Journal of International Medical Research, 48(1), 300060519898008.
doi: 10.1177/0300060519898008
pubmed: 31948307
Libório, A. B., Santos, J. P., Minete, N. F., Diógenes Cde, A., Soares, A. P., Queiroz, A. L., et al. (2012). Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function. PLoS One, 7(5), e37763.
doi: 10.1371/journal.pone.0037763
pubmed: 22662214
pmcid: 3360627
Canetta, P. A., Troost, J. P., Mahoney, S., Kogon, A. J., Carlozzi, N., Bartosh, S. M., et al. (2019). Health-related quality of life in glomerular disease. Kidney International, 95(5), 1209–1224.
doi: 10.1016/j.kint.2018.12.018
pubmed: 30898342
pmcid: 6743723
Szklarzewicz, J., & HONUS Advisory Board Members and HONUS Study Team. (2021). PO1479: Humanistic burden of rare kidney diseases; understanding the impact of FSGS and IgAN on patients and caregivers: The HONUS rationale and study design. American Society of Nephrology, Kidney Week; November 4, 2021; Orlando, FL.
ClinicalTrials.gov NCT05200871: Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (HONUS). https://classic.clinicaltrials.gov/ct2/show/results/NCT05200871?view=results . Accessed on: February 22, 2024.
Kosinski, M., Ware, J., Turner-Bowker, D., & Gandek, B. (2007). User’s manual for the Sf-12v2 health survey: With a supplement documenting the Sf-12
Peipert, J. D., Nair, D., Klicko, K., Schatell, D. R., & Hays, R. D. (2019). Kidney disease quality of life 36-item short form survey (KDQOL-36) normative values for the United States dialysis population and new single summary score. Journal of the American Society of Nephrology, 30(4), 654–663.
doi: 10.1681/ASN.2018100994
pubmed: 30898868
pmcid: 6442334
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993). The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics, 4(5), 353–365.
doi: 10.2165/00019053-199304050-00006
pubmed: 10146874
Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097.
doi: 10.1001/archinte.166.10.1092
pubmed: 16717171
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613.
doi: 10.1046/j.1525-1497.2001.016009606.x
pubmed: 11556941
pmcid: 1495268
National Health and Wellness Survey (NHWS) Cerner Enviza. https://www.cernerenviza.com/real-world-data/national-health-and-wellness-survey-nhws . Accessed on: December 14, 2023.
Gruenberger, J. B., Vietri, J., Keininger, D. L., & Mahler, D. A. (2017). Greater dyspnea is associated with lower health-related quality of life among European patients with COPD. Int J Chron Obstruct Pulmon Dis, 12, 937–944.
doi: 10.2147/COPD.S123744
pubmed: 28360517
pmcid: 5365328
Gupta, S., Isherwood, G., Jones, K., & Van Impe, K. (2015). Assessing health status in informal schizophrenia caregivers compared with health status in non-caregivers and caregivers of other conditions. Bmc Psychiatry, 15, 162.
doi: 10.1186/s12888-015-0547-1
pubmed: 26194890
pmcid: 4509463
Gupta, S., Kwan, P., Faught, E., Tsong, W., Forsythe, A., & Ryvlin, P. (2016). Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: An analysis from the National Health and Wellness Survey. Epilepsy & Behavior, 55, 146–156.
doi: 10.1016/j.yebeh.2015.12.018
Gupta, S., Richard, L., & Forsythe, A. (2015). The humanistic and economic burden associated with increasing body mass index in the EU5. Diabetes Metab Syndr Obes, 8, 327–338.
doi: 10.2147/DMSO.S83696
pubmed: 26229497
pmcid: 4516187
Gupta, S., Ryvlin, P., Faught, E., Tsong, W., & Kwan, P. (2017). Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil. Epilepsia Open, 2(2), 199–213.
doi: 10.1002/epi4.12050
pubmed: 29588949
pmcid: 5719850
Pavord, I. D., Mathieson, N., Scowcroft, A., Pedersini, R., Isherwood, G., & Price, D. (2017). The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β(2)-agonists in the United Kingdom: A cross-sectional analysis. NPJ Prim Care Respir Med, 27(1), 17.
doi: 10.1038/s41533-017-0014-1
pubmed: 28270657
pmcid: 5434793
Strader, C., Goren, A., & DiBonaventura, M. Prevalence of combinations of diabetes complications across NHANES and NHWS. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); August 26, 2016; Dublin, Ireland.
Kalton, G., & Flores-Cervantes, I. (2003). Weighting methods. J off Stat, 19(2), 81.
Hays, R. D., & Morales, L. S. (2001). The RAND-36 measure of health-related quality of life. Annals of Medicine, 33(5), 350–357.
doi: 10.3109/07853890109002089
pubmed: 11491194
Stuart, E. A. (2010). Matching methods for causal inference: A review and a look forward. Stat Sci, 25(1), 1–21.
doi: 10.1214/09-STS313
pubmed: 20871802
pmcid: 2943670
Davern, M., & Strief, J. IPUMS user note: Issues concerning the calculation of standard errors (i.e., variance estimation) using IPUMS data products. https://international.ipums.org/international/resources/misc_docs/user_note_variance.pdf . Accessed on: January 7, 2024.
Sullivan, G. M., & Feinn, R. (2012). Using effect size-or why the p value is not enough. J Grad Med Educ, 4(3), 279–282.
doi: 10.4300/JGME-D-12-00156.1
pubmed: 23997866
pmcid: 3444174
Ware, J. E. (2000). Jr. SF-36 health survey update. Spine (Phila Pa 1976), 25(24), 3130–3139.
doi: 10.1097/00007632-200012150-00008
pubmed: 11124729
Jhaveri, K. D., Bensink, M. E., Bunke, M., Briggs, J. A., Cork, D. M. W., & Jeyabalan, A. (2023). Humanistic and economic burden of IgA nephropathy: Systematic literature reviews and narrative synthesis. Pharmacoecon Open, 7(5), 709–722.
doi: 10.1007/s41669-023-00415-0
pubmed: 37103750
pmcid: 10471536
Marsh, K., Ho, K. A., Lo, R., Zaour, N., George, A. T., & Cook, N. S. (2021). Assessing patient preferences in rare diseases: direct preference elicitation in the rare chronic kidney disease, immunoglobulin A nephropathy. Patient, 14(6), 837–847.
doi: 10.1007/s40271-021-00521-3
pubmed: 34008165
pmcid: 8131174
Mizerska-Wasiak, M., Adamczuk, D., Cichoń-Kawa, K., Miklaszewska, M., Szymanik-Grzelak, H., Pietrzyk, J. A., et al. (2021). Health-related quality of life in children with immunoglobulin a nephropathy - results of a multicentre national study. Arch Med Sci, 17(1), 84–91.
doi: 10.5114/aoms.2020.100367
pubmed: 33488859
Ndife, B., Kroes, M., Aldworth, C., George, A. T., Prieto, L., DeCourcy, J. (2023). Impact of immunoglobulin A nephropathy on work, productivity, and activity impairment in the United States: Results from a real-world study. Academy of Managed Care Pharmacy Meeting; March 21–24, 2023; San Antonio, TX.
Gilbertson, E. L., Krishnasamy, R., Foote, C., Kennard, A. L., Jardine, M. J., & Gray, N. A. (2019). Burden of care and quality of life among caregivers for adults receiving maintenance dialysis: A systematic review. American Journal of Kidney Diseases, 73(3), 332–343.
doi: 10.1053/j.ajkd.2018.09.006
pubmed: 30454885
Tyagi, N., Aasaithambi, S., Chauhan, J., George, A., & Zaour, N. (2019). PUK32: Patient insights for immunoglobulin A nephropathy (IgAN) using social media listening. Value In Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 22, S919.
Zhou, M., Besink, M., Hazra, N. C., Xu, C., Hendry, B. M., Sharpe, C. C. (2022). TH-PO496: Health state utility values for immunoglobulin A nephropathy (IgAN). American Society of Nephrology Kidney Week Meeting; November 3, 2022; Orlando, FL.
Caster, D. J., Abner, C. W., Walker, P. D., Wang, K., Heo, J., Rava, A. R., et al. (2023). Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep, 8(9), 1792–1800.
doi: 10.1016/j.ekir.2023.06.016
pubmed: 37705898
pmcid: 10496075
Merakoi Patient advocacy: Why do women advocate more than men? https://merakoi.com/patient-advocacy-why-do-women-advocate-more-than-men/ . Accessed on: February 20, 2024.